SCHEMBL1734754

SCHEMBL1734754

O=C(O)C1CN(S(=O)(=O)c2ccccc2)C(=O)N1c1ccccc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 0.44
CYP2C9 P11712 2/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43
CYP2C19 P33261 1/20 0.43
NOTUM Q6P988 1/20 0.43
MMP2 P08253 2/20 0.40
BCL2L1 Q07817 1/20 0.39
BAK1 Q16611 1/20 0.39
PKM P14618 1/20 0.39
ALDH1A1 P00352 2/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39
AKR1C3 P42330 2/20 0.38
AKR1C1 Q04828 1/20 0.38
HSD11B1 P28845 1/20 0.38
KMT2A Q03164 3/20 0.38
USP2 O75604 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1734756 1.00 MCL1 (0.44) MCL1CYP2C9CYP3A4CYP2D6CYP2C19
SCHEMBL1736976 0.89 FAAH (0.44) MCL1NOTUMPOLBAKR1C3HSD11B1
SCHEMBL1736975 0.89 FAAH (0.44) MCL1NOTUMPOLBAKR1C3HSD11B1
SCHEMBL1734637 0.87 MMP2 (0.49) MCL1CYP2C9CYP3A4CYP2D6CYP2C19
SCHEMBL1736510 0.83 NOTUM (0.41) MCL1NOTUMMAPTKMT2A
SCHEMBL1736512 0.81 GAA (0.40) MCL1CYP2C9CYP3A4CYP2C19NOTUM
SCHEMBL1735544 0.78 HSD11B1 (0.45) ALDH1A1HSD11B1
SCHEMBL1735542 0.78 HSD11B1 (0.45) ALDH1A1HSD11B1
SCHEMBL1735627 0.77 MAPT (0.49) CYP2C9CYP2C19ALDH1A1MAPTKMT2A
SCHEMBL1735625 0.77 MAPT (0.49) CYP2C9CYP2C19ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2142533-B1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-11-16 EP disclosed
WO-2011069003-A3 METHODS AND SYSTEMS FOR THE TREATMENT OF ANXIETY DISORDERS AND DISORDERS WITH PSYCHOTIC FEATURES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-10-27 WO disclosed
CN-101641348-A Imidazolidinone derivatives HOFFMANN LA ROCHE CH 2010-02-03 CN disclosed
EP-2142533-A1 IMIDAZOLIDINONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-01-13 EP disclosed
US-7625902-B2 Imidazolidinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-12-01 US disclosed
WO-2008119657-A1 IMIDAZOLIDINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-10-09 WO disclosed
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2008-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080242677-A1 IMIDAZOLIDINONE DERIVATIVES NR1H2, NR1H3, NR1I2 MCL1 1773/4885CYP2C9 292/4885CYP3A4 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.